Algeria has been recording thousands of hemophilia cases in recent years, prompting urgent discussions on treatment strategies and full patient care. Professor Mostafa Chelghoum, a distinguished pharmacist at the University Hospital of Sidi Bel Abbès, recently noted the significant global and national prevalence of this rare blood disorder. Chelghoum stated, "Hemophilia is a rare and chronic disease, with 42,000 patients worldwide and about 2100 patients in Algeria, estimating that 90 percent are adolescents and 55 percent are children." The severity and long-term implications of the condition show the critical need for effective management. A recent training session, focused on 'Foundational Values for Investment in Hemophilia Treatment and its Long-Term Impact on the Patient and Society', aimed to address these pressing concerns and explore sustainable solutions for patient well-being.
Understanding Hemophilia and Its Impact
Hemophilia affects approximately 1 in every 5,000 male births globally, making it a significant public health challenge. The condition, which is hereditary, silent, and chronic, often does not present immediately noticeable bleeding symptoms, making early diagnosis and intervention key. This means that individuals can carry the disorder without obvious signs until a bleeding episode occurs. Hemophilia type 'A' is more prevalent than type 'B', accounting for the majority of cases. Patients with the disorder typically require on-demand treatment to manage acute bleeding episodes, which can arise from injuries or even spontaneously. Some individuals need preventive treatment, also known as prophylaxis, to avert bleeding altogether and minimize long-term joint damage. In Algeria, the demographic breakdown of patients is particularly striking, with an estimated 90% of hemophilia patients being adolescents and 55% children, noting the profound impact on younger populations and the need for specialized pediatric care.
Barriers to Patient Activity
Professor Amal Jenouni noted that exercise restrictions significantly impact the quality of life for many hemophilia patients. Jenouni stated that 17% of adult patients and 8% of child patients experience limitations that prevent them from exercising, thereby affecting their overall physical and mental well-being. She emphasized the benefits of certain activities, noting, "Swimming is a good step for treatment," as it offers a low-impact way to maintain physical fitness without excessive risk of injury.
To address these multifaceted challenges and improve patient outcomes, several key recommendations have been made. These include the urgent need to avoid medication shortages, ensuring a consistent supply of essential treatments. There is a strong call for training doctors across various specialties, not just hematologists, to improve early recognition and full management of hemophilia. Raising awareness about hemophilia in schools is also vital, helping to educate teachers, parents, and students about the condition, fostering a more inclusive environment, and ensuring appropriate support for affected children. These measures collectively aim to improve the standard of care and facilitate greater, safer participation in physical activities for patients, ultimately enhancing their quality of life.
The 'Roche' laboratory recently organized a training session to discuss such critical issues and foster collaboration among healthcare professionals. The event, which took place at the prestigious 'Sofitel' hotel in Algiers, brought together a diverse group of stakeholders, including medical experts, pharmacists, and patient advocates. The session explored foundational values for investment in hemophilia treatment, emphasizing its long-term impact on both the individual patient and society at large.
Expert Recommendations and Future Outlook
Professor Amal Jenouni, a distinguished blood diseases specialist at the University Hospital of Annaba, stated that Algeria currently has over 1564 patients with hemophilia, based on data from the National Registry collected from only nine experimental centers. This figure likely underestimates the true prevalence, showing the need for more full data collection. Jenouni emphasized the critical need for prompt medical intervention, noting, "This disease is silent and chronic and hereditary, where bleeding symptoms cannot be observed, and it requires rapid and timely care for patients, especially when they are injured in an accident to stop the bleeding." The swift administration of treatment is critical to prevent severe complications. Professor Mostafa Chelghoum further noted the detrimental effects of the disease on patients' health and quality of life and advocated strongly for a national preventive plan designed to ensure optimal patient care across the country. Patients require rapid and timely care, particularly after an accident, to effectively stop bleeding and prevent further damage. Additionally, home treatment, which can significantly improve patient autonomy and access to care, necessitates prior understanding of the disease and the timely administration of recommended treatment to prevent complications that could potentially lead to long-term disability. Jenouni previously indicated that swimming could be a beneficial therapeutic activity, stating, "Swimming is a good step for treatment," promoting physical activity in a safe manner.
